Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma

NCT01771107 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01771107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01771107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Completed
Start date
March 8, 2013
Completion date
March 21, 2024
Enrollment
41 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

aids-related hodgkin lymphoma, ann arbor stage ii hodgkin lymphoma, ann arbor stage iia hodgkin lymphoma, ann arbor stage iib hodgkin lymphoma, ann arbor stage iii hodgkin lymphoma, ann arbor stage iiia hodgkin lymphoma, ann arbor stage iiib hodgkin lymphoma, ann arbor stage iv hodgkin lymphoma, ann arbor stage iva hodgkin lymphoma, ann arbor stage ivb hodgkin lymphoma, classic hodgkin lymphoma, hiv infection